Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 3/20 | 0.76 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.64 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.64 |
| ▸ | CFTR | P13569 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821422 | 0.97 | VCP (0.76) | VCPALOX5AMY1ACFTRNPY5R | |
| SCHEMBL1821894 | 0.89 | ALOX5 (0.79) | VCPALOX5AMY1ANPY5RMAPT | |
| SCHEMBL7111888 | 0.86 | VCP (0.76) | VCPALOX5AMY1ACFTRMAPT | |
| SCHEMBL206229 | 0.86 | VCP (0.76) | VCPALOX5AMY1ACFTRMAPT | |
| SCHEMBL207572 | 0.86 | VCP (0.76) | VCPALOX5AMY1ACFTRNPY5R | |
| SCHEMBL1892520 | 0.86 | VCP (0.76) | VCPALOX5AMY1ACFTRMAPT | |
| SCHEMBL31126469 | 0.83 | ALOX5 (0.71) | VCPALOX5AMY1ACFTRNPY5R | |
| SCHEMBL1821487 | 0.83 | VCP (0.71) | VCPALOX5AMY1ACFTRMAPT | |
| SCHEMBL205600 | 0.83 | MEN1 (0.71) | VCPMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12298023 | 0.83 | CFTR (0.74) | VCPALOX5CFTRNPY5RMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | claimed |
| US-6586453-B2 | Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | claimed |
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6586453-B2 | Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001074793-A2 | SUBSTITUTED THIAZOLES AND THE USE THEREOF AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044545-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | VCP 2778/4885ALOX5 2040/4885AMY1A 42/4885 |
| US-20030220380-A1 | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | VCP 2778/4885ALOX5 2040/4885AMY1A 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.